CyPath® Lung detects Stage 1A lung cancer missed by standard tests in case study

bioAffinity Technologies, Inc.

CyPath Lung identified Stage 1A invasive mucinous adenocarcinoma in a 62-year-old female with heavy smoking history and COPD.
Previous PET scan showed low uptake; blood-based risk test indicated only 11% malignancy risk; serial LDCTs appeared stable.
CyPath test result of 0.56 classified as 'likely malignancy', prompting surgical wedge resection in June 2025.
Final pathology confirmed Stage 1A cancer; patient quit smoking in March 2025; surgery enabled curative intervention.
Test uses AI and flow cytometry on sputum to detect cancer cells; previously showed 92% sensitivity in clinical study.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.